Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis.

Sidhom JW, Bessell CA, Havel JJ, Kosmides A, Chan TA, Schneck JP.

Cancer Immunol Res. 2018 Feb;6(2):151-162. doi: 10.1158/2326-6066.CIR-17-0114. Epub 2017 Dec 20.

PMID:
29263161
2.

Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival.

Vandeven N, Lewis CW, Makarov V, Riaz N, Paulson KG, Hippe D, Bestick A, Doumani R, Marx T, Takagishi S, Chan TA, Choi J, Nghiem P.

Clin Cancer Res. 2018 Feb 15;24(4):963-971. doi: 10.1158/1078-0432.CCR-17-1678. Epub 2017 Dec 15.

PMID:
29246939
3.

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA.

Science. 2018 Feb 2;359(6375):582-587. doi: 10.1126/science.aao4572. Epub 2017 Dec 7.

PMID:
29217585
4.

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.

Turcan S, Makarov V, Taranda J, Wang Y, Fabius AWM, Wu W, Zheng Y, El-Amine N, Haddock S, Nanjangud G, LeKaye HC, Brennan C, Cross J, Huse JT, Kelleher NL, Osten P, Thompson CB, Chan TA.

Nat Genet. 2018 Jan;50(1):62-72. doi: 10.1038/s41588-017-0001-z. Epub 2017 Nov 27.

PMID:
29180699
5.

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O; Australian Pancreatic Cancer Genome Initiative; Garvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; University of Glasgow; St Vincent’s Hospital; QIMR Berghofer Medical Research Institute; University of Melbourne, Centre for Cancer Research; University of Queensland, Institute for Molecular Bioscience; Bankstown Hospital; Liverpool Hospital; Royal Prince Alfred Hospital, Chris O’Brien Lifehouse; Westmead Hospital; Fremantle Hospital; St John of God Healthcare; Royal Adelaide Hospital; Flinders Medical Centre; Envoi Pathology; Princess Alexandria Hospital; Austin Hospital; Johns Hopkins Medical Institutes; ARC-Net Centre for Applied Research on Cancer, Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD.

Nature. 2017 Nov 23;551(7681):512-516. doi: 10.1038/nature24462. Epub 2017 Nov 8.

PMID:
29132146
6.

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, Rizvi NA, Merghoub T, Levine AJ, Chan TA, Wolchok JD, Greenbaum BD.

Nature. 2017 Nov 23;551(7681):517-520. doi: 10.1038/nature24473. Epub 2017 Nov 8.

PMID:
29132144
7.

Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions.

Dalin MG, Katabi N, Persson M, Lee KW, Makarov V, Desrichard A, Walsh LA, West L, Nadeem Z, Ramaswami D, Havel JJ, Kuo F, Chadalavada K, Nanjangud GJ, Ganly I, Riaz N, Ho AL, Antonescu CR, Ghossein R, Stenman G, Chan TA, Morris LGT.

Nat Commun. 2017 Oct 30;8(1):1197. doi: 10.1038/s41467-017-01178-z.

8.

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.

Anderson ES, Postow MA, Wolchok JD, Young RJ, Ballangrud Å, Chan TA, Yamada Y, Beal K.

J Immunother Cancer. 2017 Oct 17;5(1):76. doi: 10.1186/s40425-017-0282-x.

9.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e15. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

PMID:
29033130
10.

NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer.

Grinberg-Bleyer Y, Oh H, Desrichard A, Bhatt DM, Caron R, Chan TA, Schmid RM, Klein U, Hayden MS, Ghosh S.

Cell. 2017 Sep 7;170(6):1096-1108.e13. doi: 10.1016/j.cell.2017.08.004.

PMID:
28886380
11.

Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.

Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):797-804. doi: 10.1016/j.ijrobp.2017.06.2466. Epub 2017 Jun 30.

PMID:
28870792
12.

An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.

Walsh LA, Alvarez MJ, Sabio EY, Reyngold M, Makarov V, Mukherjee S, Lee KW, Desrichard A, Turcan Ş, Dalin MG, Rajasekhar VK, Chen S, Vahdat LT, Califano A, Chan TA.

Cell Rep. 2017 Aug 15;20(7):1623-1640. doi: 10.1016/j.celrep.2017.07.052.

13.

Dissecting microsatellite instability in colorectal cancer: one size does not fit all.

Samstein RM, Chan TA.

Genome Med. 2017 May 24;9(1):45. doi: 10.1186/s13073-017-0438-9.

14.

Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5×6Gy) conformal radiotherapy.

Lockney NA, Wang DG, Gutin PH, Brennan C, Tabar V, Ballangrud A, Pei X, Chan TA, Yamada Y, Yang TJ, Beal K.

Radiother Oncol. 2017 May;123(2):203-208. doi: 10.1016/j.radonc.2017.03.018. Epub 2017 Apr 5.

PMID:
28390657
15.

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.

Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R.

Cell. 2017 Apr 6;169(2):361. doi: 10.1016/j.cell.2017.03.036. No abstract available.

PMID:
28388418
16.

Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.

Knudsen ES, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM, Chan TA, Witkiewicz AK.

Clin Cancer Res. 2017 Aug 1;23(15):4429-4440. doi: 10.1158/1078-0432.CCR-17-0162. Epub 2017 Mar 27.

PMID:
28348045
17.

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2017 Mar 1;18(1):46. doi: 10.1186/s13059-017-1180-8. No abstract available.

18.

Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.

Ascierto ML, Makohon-Moore A, Lipson EJ, Taube JM, McMiller TL, Berger AE, Fan J, Kaunitz GJ, Cottrell TR, Kohutek ZA, Favorov A, Makarov V, Riaz N, Chan TA, Cope L, Hruban RH, Pardoll DM, Taylor BS, Solit DB, Iacobuzio-Donahue CA, Topalian SL.

Clin Cancer Res. 2017 Jun 15;23(12):3168-3180. doi: 10.1158/1078-0432.CCR-17-0270. Epub 2017 Feb 13.

PMID:
28193624
19.

PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.

Koncar RF, Chu Z, Romick-Rosendale LE, Wells SI, Chan TA, Qi X, Bahassi EM.

Oncotarget. 2017 Feb 28;8(9):15827-15837. doi: 10.18632/oncotarget.15015.

20.

Regularized quantile regression under heterogeneous sparsity with application to quantitative genetic traits.

He Q, Kong L, Wang Y, Wang S, Chan TA, Holland E.

Comput Stat Data Anal. 2016 Mar;95:222-239. doi: 10.1016/j.csda.2015.10.007. Epub 2015 Oct 24.

21.

Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM.

Ma J, Setton J, Morris L, Albornoz PB, Barker C, Lok BH, Sherman E, Katabi N, Beal K, Ganly I, Powell SN, Lee N, Chan TA, Riaz N.

Oncotarget. 2017 Feb 7;8(6):10312-10323. doi: 10.18632/oncotarget.14400.

22.

Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells.

Rajappa P, Cobb WS, Vartanian E, Huang Y, Daly L, Hoffman C, Zhang J, Shen B, Yanowitch R, Garg K, Cisse B, Haddock S, Huse J, Pisapia DJ, Chan TA, Lyden DC, Bromberg JF, Greenfield JP.

Clin Cancer Res. 2017 Jun 15;23(12):3109-3119. doi: 10.1158/1078-0432.CCR-16-1508. Epub 2016 Dec 30.

23.

Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis.

Gong Y, Schumacher SE, Wu WH, Tang F, Beroukhim R, Chan TA.

Neoplasia. 2017 Feb;19(2):75-83. doi: 10.1016/j.neo.2016.12.006. Epub 2016 Dec 27.

24.

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2016 Nov 17;17(1):231. Erratum in: Genome Biol. 2017 Mar 1;18(1):46.

25.

Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.

Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K.

Cancer Res. 2016 Nov 15;76(22):6495-6506. doi: 10.1158/0008-5472.CAN-16-1457. Epub 2016 Sep 26.

26.

Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.

Riaz N, Havel JJ, Kendall SM, Makarov V, Walsh LA, Desrichard A, Weinhold N, Chan TA.

Nat Genet. 2016 Nov;48(11):1327-1329. doi: 10.1038/ng.3677. Epub 2016 Sep 26.

27.

The head and neck cancer immune landscape and its immunotherapeutic implications.

Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG.

JCI Insight. 2016 Oct 20;1(17):e89829.

28.

Initial Report on Safety and Lesion Response of Melanoma Brain Metastases After Stereotactic Radiosurgery or Hypofractionated Radiation Therapy in Patients Receiving Concurrent Pembrolizumab.

Anderson ES, Postow MA, Young R, Chan TA, Yamada Y, Beal K.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E132. doi: 10.1016/j.ijrobp.2016.06.922. No abstract available.

PMID:
27673860
29.

The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.

Morris LG, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS, Ganly I, Singh B, Shah JP, Shaha AR, Boyle JO, Patel SG, Roman BR, Barker CA, McBride SM, Chan TA, Dogan S, Hyman DM, Berger MF, Solit DB, Riaz N, Ho AL.

JAMA Oncol. 2016 Jul 21. doi: 10.1001/jamaoncol.2016.1790. [Epub ahead of print]

30.

Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma.

Hellmann M, Rizvi N, Wolchok JD, Chan TA.

Mol Cell Oncol. 2015 May 26;3(1):e1048929. doi: 10.1080/23723556.2015.1048929. eCollection 2016 Jan.

31.

Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations.

Roy DM, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J, Bose P, Lee W, Chan TA.

Cancer Cell. 2016 May 9;29(5):737-750. doi: 10.1016/j.ccell.2016.03.025.

32.

Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.

Mandal R, Chan TA.

Cancer Discov. 2016 Jul;6(7):703-13. doi: 10.1158/2159-8290.CD-16-0146. Epub 2016 Apr 22. Review.

33.

Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, Wang Q, Armenia J, West L, Dogan S, Wang L, Ramaswami D, Ho AL, Ganly I, Solit DB, Berger MF, Schultz ND, Reis-Filho JS, Chan TA, Morris LG.

Clin Cancer Res. 2016 Sep 15;22(18):4623-33. doi: 10.1158/1078-0432.CCR-16-0637. Epub 2016 Apr 21.

34.

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.

Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R.

Cell. 2016 Feb 25;164(5):1073. doi: 10.1016/j.cell.2015.10.020. Epub 2016 Feb 25. No abstract available.

35.

The role of neoantigens in response to immune checkpoint blockade.

Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA.

Int Immunol. 2016 Aug;28(8):411-9. doi: 10.1093/intimm/dxw019. Epub 2016 Apr 5. Review.

36.

Corticosteroids compromise survival in glioblastoma.

Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D.

Brain. 2016 May;139(Pt 5):1458-71. doi: 10.1093/brain/aww046. Epub 2016 Mar 28.

37.

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C.

Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.

38.

FAT1 mutations cause a glomerulotubular nephropathy.

Gee HY, Sadowski CE, Aggarwal PK, Porath JD, Yakulov TA, Schueler M, Lovric S, Ashraf S, Braun DA, Halbritter J, Fang H, Airik R, Vega-Warner V, Cho KJ, Chan TA, Morris LG, ffrench-Constant C, Allen N, McNeill H, Büscher R, Kyrieleis H, Wallot M, Gaspert A, Kistler T, Milford DV, Saleem MA, Keng WT, Alexander SI, Valentini RP, Licht C, Teh JC, Bogdanovic R, Koziell A, Bierzynska A, Soliman NA, Otto EA, Lifton RP, Holzman LB, Sibinga NE, Walz G, Tufro A, Hildebrandt F.

Nat Commun. 2016 Feb 24;7:10822. doi: 10.1038/ncomms10822.

39.

Immunotherapy and Oncogenic Pathways: The PTEN Connection.

Rizvi NA, Chan TA.

Cancer Discov. 2016 Feb;6(2):128-9. doi: 10.1158/2159-8290.CD-15-1501.

40.

Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival.

Morris LG, Riaz N, Desrichard A, Şenbabaoğlu Y, Hakimi AA, Makarov V, Reis-Filho JS, Chan TA.

Oncotarget. 2016 Mar 1;7(9):10051-63. doi: 10.18632/oncotarget.7067.

41.

Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.

Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, Stafstrom K, Moshiri A, Yelistratova L, Levinsohn J, Chan TA, Nghiem P, Lifton RP, Choi J.

Oncotarget. 2016 Jan 19;7(3):3403-15. doi: 10.18632/oncotarget.6494.

42.

Integrated genomic characterization of IDH1-mutant glioma malignant progression.

Bai H, Harmancı AS, Erson-Omay EZ, Li J, Coşkun S, Simon M, Krischek B, Özduman K, Omay SB, Sorensen EA, Turcan Ş, Bakırcığlu M, Carrión-Grant G, Murray PB, Clark VE, Ercan-Sencicek AG, Knight J, Sencar L, Altınok S, Kaulen LD, Gülez B, Timmer M, Schramm J, Mishra-Gorur K, Henegariu O, Moliterno J, Louvi A, Chan TA, Tannheimer SL, Pamir MN, Vortmeyer AO, Bilguvar K, Yasuno K, Günel M.

Nat Genet. 2016 Jan;48(1):59-66. doi: 10.1038/ng.3457. Epub 2015 Nov 30.

43.

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma.

Chan TA, Wolchok JD, Snyder A.

N Engl J Med. 2015 Nov 12;373(20):1984. doi: 10.1056/NEJMc1508163. No abstract available.

44.

Cancer Neoantigens and Applications for Immunotherapy.

Desrichard A, Snyder A, Chan TA.

Clin Cancer Res. 2016 Feb 15;22(4):807-12. doi: 10.1158/1078-0432.CCR-14-3175. Epub 2015 Oct 29. Review.

45.

Genetics and immunology: reinvigorated.

Snyder A, Makarov V, Hellmann M, Rizvi N, Merghoub T, Wolchok JD, Chan TA.

Oncoimmunology. 2015 Apr 14;4(10):e1029705. eCollection 2015 Oct.

46.

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.

Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R.

Cell. 2015 Aug 27;162(5):974-86. doi: 10.1016/j.cell.2015.07.011. Erratum in: Cell. 2016 Feb 25;164(5):1073. Buhu, Sadna [corrected to Budhu, Sadna]; Mergoub, Taha [corrected to Merghoub, Taha]. Cell. 2017 Apr 6;169(2):361.

47.

Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases.

Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH, Yang TJ, Rosenblum MK, Ballangrud Å, Young RJ, Zhang Z, Beal K.

J Neurooncol. 2015 Oct;125(1):149-56. doi: 10.1007/s11060-015-1881-3. Epub 2015 Aug 26.

48.

Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.

Peyser ND, Du Y, Li H, Lui V, Xiao X, Chan TA, Grandis JR.

PLoS One. 2015 Aug 12;10(8):e0135750. doi: 10.1371/journal.pone.0135750. eCollection 2015.

49.

Genomic landscape of adenoid cystic carcinoma of the breast.

Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L, Cyrta J, Piscuoglio S, Wen HC, Lim RS, Shen R, Schultheis AM, Wen YH, Edelweiss M, Mariani O, Stenman G, Chan TA, Colombo PE, Norton L, Vincent-Salomon A, Reis-Filho JS, Weigelt B.

J Pathol. 2015 Oct;237(2):179-89. doi: 10.1002/path.4573. Epub 2015 Jul 14.

50.

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J.

N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.

Supplemental Content

Loading ...
Support Center